Bionano Stock Today

BNGO -  USA Stock  

USD 2.32  0.17  7.91%

Market Performance
0 of 100
Odds Of Distress
Less than 3
Bionano Genomics is selling for 2.32 as of the 22nd of January 2022. This is a 7.91 percent increase since the beginning of the trading day. The stock's open price was 2.15. Bionano Genomics has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Bionano Genomics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of December 2021 and ending today, the 22nd of January 2022. Please note, there could be an existing legal relationship between Bionano Genomics (BNGO) and Bionano Genomics (BNGOU). Click here to learn more.
Bionano Genomics, Inc., a genome analysis company, provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. The company was founded in 2006 and is headquartered in San Diego, California. The company has 278.85 M outstanding shares of which 40.17 M shares are currently shorted by private and institutional investors with about 3.76 trading days to cover. More on Bionano Genomics

Bionano Genomics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Bionano Genomics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bionano Genomics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Bionano Genomics generated a negative expected return over the last 90 days
Bionano Genomics has high historical volatility and very poor performance
Bionano Genomics is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 15.67 M. Net Loss for the year was (61.22 M) with profit before overhead, payroll, taxes, and interest of 2.77 M.
Bionano Genomics currently holds about 326.07 M in cash with (58.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.13.
Latest headline from www.marketscreener.com: Bionano Genomics Announces Record Daily Attendance for 2022 Symposium with 63 percent Increase Relative to Last Year - marketscreener.com
Bionano Genomics Fama & French Measuring and Control
Measuring and Control
Fama & French Classification
Bionano Genomics SEC Filings
Bionano Genomics SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameBionano Genomics
Related EntityBNGOU (Bionano Genomics)
President CEO, DirectorErik Holmlin  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
  Measuring and Control
Average Analyst Recommendation
Analysts covering Bionano Genomics report their recommendations after researching Bionano Genomics' financial statements, talking to executives and customers, or listening in on Bionano Genomics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Bionano Genomics. The Bionano consensus assessment is calculated by taking the average forecast from all of the analysts covering Bionano Genomics.
Strong Buy4 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Bionano Genomics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Bionano Genomics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 5 - HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares129.4 M119.9 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted129.4 M119.9 M
Significantly Up
Increasing
Slightly volatile
Total Assets75 M69.5 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities27 M29.2 M
Significantly Down
Increasing
Slightly volatile
Current Assets58.1 M53.8 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities13 M10.3 M
Significantly Up
Increasing
Stable
Total Debt16.7 M18.8 M
Fairly Down
Increasing
Slightly volatile
Gross Margin0.30.29
Sufficiently Up
Decreasing
Slightly volatile
Asset Turnover0.220.21
Sufficiently Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Bionano Genomics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
Bionano Genomics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Bionano Genomics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bionano Genomics' financial leverage. It provides some insight into what part of Bionano Genomics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Bionano Genomics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Bionano Genomics deploys its capital and how much of that capital is borrowed.
Liquidity
Bionano Genomics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 14.87 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Bionano Genomics has a current ratio of 18.93, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(37.21 Million)Share
Bionano Genomics (BNGO) is traded on NASDAQ Exchange in USA. It is located in 9540 Towne Centre Drive and employs 147 people. Bionano Genomics is listed under Measuring and Control category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 897.51 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bionano Genomics's market, we take the total number of its shares issued and multiply it by Bionano Genomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Bionano Genomics conducts business under Healthcare sector and is part of Diagnostics & Research industry. The entity has 278.85 M outstanding shares of which 40.17 M shares are currently shorted by private and institutional investors with about 3.76 trading days to cover. Bionano Genomics currently holds about 326.07 M in cash with (58.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.13.
Check Bionano Genomics Probability Of Bankruptcy
Ownership
Bionano Genomics retains a total of 278.85 Million outstanding shares. Almost 72.0 percent of Bionano Genomics outstanding shares are held by regular investors with 2.17 (percent) owned by insiders and only 25.46 % by other corporate entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Bionano Ownership Details

Bionano Stock Price Odds Analysis

What are Bionano Genomics' target price odds to finish over the current price? Proceeding from a normal probability distribution, the odds of Bionano Genomics jumping above the current price in 90 days from now is about 92.57%. The Bionano Genomics probability density function shows the probability of Bionano Genomics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 3.2809 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bionano Genomics will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Bionano Genomics is significantly underperforming DOW.
 Odds Down 2.32HorizonTargetOdds Up 2.32 
7.39%90 days
 2.32 
92.57%
Based on a normal probability distribution, the odds of Bionano Genomics to move above the current price in 90 days from now is about 92.57 (This Bionano Genomics probability density function shows the probability of Bionano Stock to fall within a particular range of prices over 90 days) .

Bionano Genomics Historical Income Statement

Bionano Genomics Income Statement is one of the three primary financial statements used for reporting Bionano's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Bionano Genomics revenue and expense. Bionano Genomics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Bionano Genomics Weighted Average Shares Diluted is quite stable at the moment as compared to the past year. The company's current value of Weighted Average Shares Diluted is estimated at 129.35 Million View More Fundamentals

Bionano Stock Against Markets

Picking the right benchmark for Bionano Genomics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bionano Genomics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bionano Genomics is critical whether you are bullish or bearish towards Bionano Genomics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bionano Genomics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Analysis Now

   

Bond Analysis

Evaluate and analyze corporate bonds as a potential investment for your portfolios.
All  Next Launch Module

Bionano Genomics Corporate Directors

Bionano Genomics corporate directors refer to members of a Bionano Genomics board of directors. The board of directors generally takes responsibility for the Bionano Genomics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Bionano Genomics' board members must vote for the resolution. The Bionano Genomics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Darren Cai - Independent DirectorProfile
Albert Luderer - Independent DirectorProfile
Kristiina Vuori - Independent DirectorProfile
Christopher Twomey - Independent DirectorProfile
Continue to Trending Equities. Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Screener module to find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Bionano Stock analysis

When running Bionano Genomics price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine Bionano Genomics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.